Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
    • Erlebnisraum Bioökonomie
    • Innovation & Startups

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 18/08/2023

    TÜV SÜD gets UK Approved Body designation

    TÜV SÜD has received approval as a UK Approved Body (UKAB) for medical devices. With this approval, medical device manufacturers can implement UKCA certification for the UK market and CE certification for the European market in a time- and cost-efficient manner with TÜV SÜD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuev-sued-gets-uk-approved-body-designation
  • Press release - 07/08/2023

    Vegan trend in Europe: In Germany, milk substitutes from plants are most popular alternative

    Germany has the most active market, Southern Europe wants more variety, and people in Poland find dairy substitutes too expensive, according to a recent study by the University of Hohenheim.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vegan-trend-europe-germany-milk-substitutes-plants-are-most-popular-alternative
  • Press release - 20/07/2023

    Animal testing under REACH: bringing numbers into the debate

    So far, 4.2 million animal tests under the REACH chemical regulation: A study from Konstanz and Baltimore quantifies the number of animals that died for the hazard assessment of chemicals in the chemical industry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tierversuche-durch-reach-zahlen-die-debatte-bringen
  • Press release - 20/07/2023

    Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention

    A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal cancer, from the anal microbiome of people with HIV (PWH). PWH are at a significantly higher risk of developing anal cancer. Current screening methods, such as anal cytology, have low specificity for detecting HSIL, which hinders the prevention of anal cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/anal-cancer-screening-new-microbiome-associated-biomarkers-could-improve-prevention
  • Press release - 13/06/2023

    AutoProNano – international cooperation for in vitro and in vivo diagnostics

    The AutoProNano German/French collaborative project involves developing a process for the automated production of nanoparticles for in vitro and in vivo diagnostics. The project is being launched within the smart analytics cooperation network. This international initiative has been funded by the Central Innovation Programme for SMEs (ZIM) of the German Federal Ministry for Economic Affairs and Climate Action (BMWK) since May 2020.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/autopronano-international-cooperation-vitro-and-vivo-diagnostics
  • Press release - 05/06/2023

    New findings about human metabolic processes

    Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes
  • Press release - 08/05/2023

    CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

    Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates. Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-dosing-first-participant-combined-phase-12-study-multivalent-modified-influenza-vaccine-candidates-developed-c
  • Press release - 04/05/2023

    Gamma delta T cells can fight aggressive breast cancer

    Triple-negative breast cancer (TNBC) is the most aggressive and deadly form of breast cancer with limited treatment options. Tumor growth and relapse of TNBC are driven by breast cancer stem cells, and improved therapies that can eliminate those hardy cells are urgently needed. Researchers from the University of Frieburg discovered that coordinated differentiation and changes in the metabolism of breast cancer stem cells make them invisible for…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gamma-delta-t-cells-can-fight-aggressive-breast-cancer
  • Development of anti-tumour agents - 20/03/2023 Drawing of the ER membrane with Sec61 channel to which the B-306 molecule binds. A pink arrow illustrates the calcium release into the cytosol.

    Targeting the protective shield of cancers

    Cancer cells have different mechanisms to help them escape destruction by the immune system. Solid tumours, for example, are often surrounded by a protective layer of lactate, which has a strong immunosuppressive effect. WMT AG from Heidelberg is developing small drug molecules that reduce lactate production and thus make cancer cells vulnerable to immune system attacks.

    https://www.gesundheitsindustrie-bw.de/en/article/news/targeting-protective-shield-cancers
  • Event - 25/04/2023

    4C Close up – Insights into C2 | Requirements engineering & good product development

    Online, Online-Seminar
    https://www.gesundheitsindustrie-bw.de/en/event/4c-close-insights-c2-requirements-engineering-good-product-development
  • Press release - 31/01/2023

    ERC Consolidator Grants for Two Researchers from KIT

    In the 2022 allocation round for the award of the prestigious Consolidator Grants of the European Research Council, researchers of Karlsruhe Institute of Technology (KIT) have been successful. For their projects in the fields of photovoltaics and medical sensor technology, physicist Ulrich W. Paetzold and chemist Frank Biedermann will receive approximately two million euros over the next five years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/erc-consolidator-grants-fuer-zwei-forscher-des-kit
  • Press release - 24/01/2023

    Controlling neural exoskeletons more precisely with diamond sensors

    Brain-computer interfaces are able to restore some mobility to paralyzed people by controlling exoskeletons. However, more complex control signals cannot yet be read from the head surface because conventional sensors are not sensitive enough. A collaboration of Fraunhofer IAF, Charité – Universitätsmedizin Berlin, University of Stuttgart and other industrial partners has taken up this challenge.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mit-diamant-sensoren-neurale-exoskelette-praeziser-steuern
  • Press release - 23/01/2023

    Brain stem cells are contolled by interferon during the entire lifetime

    Interferons represent the first line of defence against viral infections and are at the same time an important cause of the age-related loss of function of brain stem cells. Scientists from the German Cancer Research Center (DKFZ) and the University of Heidelberg have now shown in mice that interferon regulates the activity and self-renewal of brain stem cells throughout life.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hirnstammzellen-lebenslaenglich-unter-interferon-kontrolle
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Funding

    IHI call 3

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 15/03/2023
    https://www.gesundheitsindustrie-bw.de/en/database/funding/ihi-call-3
  • Press release - 06/01/2023

    CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-positive-data-joint-covid-19-and-flu-mrna-vaccine-development-programs
  • Press release - 05/01/2023

    Formation of pores in mitochondrial membrane elucidated

    Mitochondria are considered to be the power plants of cells and are essential for human metabolism. Dysfunction in 40 percent of mitochondrial proteins are associated with human diseases, which is why mitochondria also play an important role in medical research. A previously unexplained process in the complex mitochondria was the formation of their barrel pores.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/formation-pores-mitochondrial-membrane-elucidated
  • Press release - 20/12/2022

    Enzyme inhibition promotes bone formation and curbs the development of bone metastases

    In our bones, specialized cells called osteoblasts are responsible for building up bone substance. A team of researchers led by scientists from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim* and the University Medical Center Hamburg Eppendorf has now identified an enzyme that controls the activity of osteoblasts.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/enzyme-inhibition-promotes-bone-formation-and-curbs-development-bone-metastases
  • Press release - 29/11/2022

    Prototype funding for two Konstanz projects

    Chemical building blocks from plastic waste; Reducing the risk of falls using virtual orientation aids: Konstanz chemists Manuel Häußler and Lukas Odenwald as well as sport scientist Lorenz Assländer receive Baden-Württemberg prototype funding for their transfer projects "Waste2DCA" and "Augmented Balance".

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/doppelter-erfolg-der-prototypenfoerderung
  • Press release - 24/11/2022

    Green chemistry: BAM investigates pharmaceutical production without solvents and CO2 emissions

    The Bundesanstalt für Materialforschung und -prüfung (BAM) is developing a more sustainable process to produce active pharmaceutical ingredients in a major EU project: The pilot project is intended to demonstrate the advantages of mechanochemistry for more environmentally friendly and CO2-neutral pharmaceutical production.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gruene-chemie-bam-erforscht-arzneimittelproduktion-ohne-loesungsmittel-und-co2-ausstoss
  • Press release - 18/11/2022

    Leading Swiss laboratory equipment manufacturer Hamilton Bonaduz AG buys Freiburg-based microfluidic technology company BioFluidix GmbH

    BioFluidix GmbH, a spin-off resulting from the cooperation between Hahn-Schickard and the Department of Microsystems Engineering at the University of Freiburg, is now part of the Swiss Hamilton Bonaduz AG.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fuehrender-laborgeraetehersteller-hamilton-bonaduz-ag-kauft-freiburger-mikrodosierunternehmen-biofluidix-gmbh
  • Press release - 17/11/2022

    MEDICA and COMPAMED present themselves as extremely vital platforms in turbulent times

    MEDICA and COMPAMED continue to develop in an extremely vital manner. The world's leading medical trade fair and the international No. 1 for the medical technology supply sector once again impressively underscored their positive results from the previous year with strong numbers – despite continuing adverse conditions. A significant increase in bookings on the part of the exhibiting companies was followed after four days by a marked increase…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/medica-und-compamed-praesentieren-sich-als-aeusserst-vitale-plattformen-bewegten-zeiten
  • Press release - 15/11/2022

    Silicone Sponge Captures Unknown Bacteria

    From human intestines to the bottom of the sea: Microorganisms populate nearly any habitat, no matter how hostile it is. Their great variety of survival strategies is of huge potential in biotechnology. Most of these organisms, however, are unknown, because they cannot be cultivated.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/silikonschwamm-spuert-unbekannte-bakterien-auf
  • Press release - 24/10/2022

    How tumors suppress the development of metastases

    Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
  • Press release - 20/10/2022

    University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

    University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/universitaet-tuebingen-und-boehringer-ingelheim-buendeln-kraefte
  • Press release - 19/10/2022

    Molecular structure of one of the most important receptors in the immune system unraveled

    Researchers from Freiburg and Harvard publish the three-dimensional structure of the B cell antigen receptor, shedding new light on its composition.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-structure-one-most-important-receptors-immune-system-unraveled
  • Press release - 19/09/2022

    How stressed tumor cells escape cell death: new mechanism discovered

    Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-stressed-tumor-cells-escape-cell-death-new-mechanism-discovered
  • Press release - 06/09/2022

    Biointelligent sensor for measuring viral activity

    Today, genome editing is almost as easy as programming software. However, the generation of viral vectors as initial material is still associated with many expensive and error-prone handling procedures. Viruses are generated via complex biological processes that have to be optimised virus-specifically in order to produce high-quality therapeutics. A new method is needed that simplifies and optimises these processes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/Biointelligent-sensor-for-measuring-viral-activity
  • Press release - 31/08/2022

    Using nanopores to detect epigenetic changes faster

    Changes known as epigenetic modifications play an important role in cancer development, among other things. Being able to analyze them quickly and reliably could, for example, contribute significantly to the further development of personalized therapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/using-nanopores-detect-epigenetic-changes-faster
  • Press release - 18/08/2022

    CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-1-clinical-study-modified-omicron-targeting-covid-19-vaccine-candidate
  • Press release - 29/06/2022

    RNA modifications in mitochondria promote invasive spread of cancer

    Mitochondria are the power plants of cells, and they contain their own genetic material and RNA molecules. Scientists from the German Cancer Research Center (DKFZ) have now discovered that certain modifications in mitochondrial RNA boost the invasive spread of cancer cells by supporting protein synthesis in mitochondria.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rna-modifications-mitochondria-promote-invasive-spread-cancer
  • Press release - 02/06/2022

    Groundbreaking ceremony for new research building on the Faculty of Engineering campus

    Dr. Nicole Hoffmeister-Kraut, Minister of Economic Affairs, Labour and Tourism of Baden-Württemberg, together with Freiburg’s Mayor Martin Horn, gives the go-ahead for the construction project on the Georges-Köhler-Allee.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/groundbreaking-ceremony-new-research-building-faculty-engineering-campus
  • Product testing under real conditions - 11/05/2022 The photo shows a modern hospital room with a nursing bed.

    INSPIRE Living Lab: a bridge between industry and the clinic

    Coming up with innovative ideas and products in the medical care area is highly relevant not only for the further development of Baden-Württemberg as a health region, but also for improving healthcare itself. However, bridging the gap between industry and the clinic often proves difficult. To drive this process forward, the INSPIRE Living Lab was opened at the University Medical Centre Mannheim in 2021.

    https://www.gesundheitsindustrie-bw.de/en/article/news/inspire-living-lab-bridge-between-industry-and-clinic
  • Press release - 28/04/2022

    Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

    Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
  • Press release - 25/04/2022

    Reprogrammed macrophages promote spread of breast cancer

    Metastatic breast cancer cells abuse macrophages, a type of immune cell, to promote the settlement of cancer metastases in the lungs. The reprogrammed macrophages stimulate blood vessel cells to secrete a cocktail of metastasis-promoting proteins that are part of the so-called metastatic niche.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-macrophages-promote-spread-breast-cancer
  • Press release - 13/04/2022

    Emmy Noether funding for research into drug resistance of blood cancer

    The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/emmy-noether-funding-research-drug-resistance-blood-cancer
  • Press release - 12/04/2022

    Technology transfer award for PCR rapid test device for infection diagnostics

    Spindiag GmbH, together with the University of Freiburg and the Hahn-Schickard-Gesellschaft für angewandte Forschung e.V., was awarded the Technology Transfer Prize 2020 from the German Physical Society (DPG) on April 09, 2022 for the development of the PCR-based rapid test system Rhonda.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/technology-transfer-award-pcr-rapid-test-device-infection-diagnostics
  • Press release - 30/03/2022

    CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

    CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
  • SolidCAR-T project - 15/03/2022 Drawing illustrating the individual steps inside a mini-factory, starting with the collection of T lymphocytes, the preparation, processing and post-processing of the CAR T cells and ending with the treatment of the patient.

    Modular ‘mini-factories’ for decentralised production of CAR T cells

    Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

    https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
  • Elastin as artificial muscle material - 02/03/2022 A small rectangular piece of protein consisting of a beige and a brown layer in a metal container that bends to one side in one picture and to the other side in a second picture.

    Artificial muscle from proteins for diverse future applications

    As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.

    https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-muscle-proteins-diverse-future-applications
  • Press release - 01/03/2022

    CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer®

    The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
  • Press release - 17/02/2022

    New organ-on-chip system enables precise monitoring of 3D tumour tissue outside the body

    A research team around Dr. Andreas Weltin, Dr. Jochen Kieninger and Johannes Dornhof from the Department of Microsystems Engineering (IMTEK) at the University of Freiburg has developed a system that, among other things, makes it possible to study the development of tumour cells outside the human body in a three-dimensional environment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-organ-chip-system-enables-precise-monitoring-3d-tumour-tissue-outside-body
  • Press release - 10/02/2022

    CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
  • Dossier - 16/12/2021 In-vivo-Gentherapien wie Zolgensma und Ex-vivo-Gentherapien wie CAR-T-Zellen.

    Advanced therapy medicinal products: gene and cell therapies

    Novel gene and cell therapies for treating incurable and hereditary diseases have raised high expectations. However, success has so far been limited to the long-established bone marrow transplants involving the administration of haematopoietic stem cells used to treat blood cancer. CAR T-cell therapies have recently emerged as a major new hope in cancer treatment.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/advanced-therapy-medicinal-products-gene-and-cell-therapies
  • Press release - 14/12/2021

    EU regulation approved: G-BA collaborates on European health technology assessment

    Today, the EU Parliament adopted the EU Regulation on Health Technology Assessment (HTA), which includes not only new medicines (including gene and cell therapies), but also medical devices.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-regulation-approved-g-ba-collaborates-european-health-technology-assessment
  • Press release - 30/11/2021

    A mould dominates the eukaryotic microbiota in Parkinson’s disease patients

    Parkinson's disease is characterised by a slow, progressive loss of nerve cells in certain brain areas. The disease is still incurable and the exact causes are unclear. The dopamine deficiency in the brain can only be controlled to some extent in the initial phase of the disease. Basic research is being conducted in an attempt to unravel the mystery of Parkinson's disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mould-dominates-eukaryotic-microbiota-parkinsons-disease-patients
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Press release - 10/11/2021

    Plasticizers can cause asthma and allergies

    Plastic products can be found everywhere in daily life, soft plastic in particular often being used for packaging or children's toys. These often contain so-called plasticizers which ensure that the material remains flexible. Because plasticizers are not bonded permanently to the plastic, they can escape from the material, meaning they can be absorbed by humans.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/plasticizers-can-cause-asthma-and-allergies
  • Funding

    EU4Health- Programme

    Funding programme, Funded by: European Union, sb_search.searchresult.label.programSubmissionDate: 31/12/2027
    https://www.gesundheitsindustrie-bw.de/en/database/funding/eu4health-programme
  • Press release - 19/10/2021

    Gips Schüle Research Award for three scientists from the University of Stuttgart

    Prof. Dr. Harald Gießen from the Institute of Physics (4) as well as Prof. Dr. Alois Herkommer and Dr. Simon Thiele from the Institute of Applied Optics at the University of Stuttgart received the Gips Schüle Research Award 2021 on October 19, 2021. The researchers were awarded the prize, which is valued at EUR 50,000.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/gips-schuele-research-award-three-scientists-university-stuttgart

Page 1 / 3

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
    • Erlebnisraum Bioökonomie
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search